UNITY Biotechnology, Inc.

UNITY Biotechnology, Inc. is a biotechnology company focused on developing therapeutics to alleviate age-related diseases, primarily targeting cellular senescence and its role in degenerative conditions. UNITY Biotechnology was founded in 2009 in Brisbane, US, by Akeem Shinholster and Nathaniel David. The company specializes in creating therapies to combat age-related health issues, notably through biologic treatments designed to eliminate senescent cells.

It had a significant funding round in May 2018, raising USD 85 mn through an IPO, which was the total amount raised over its funding history. The current CEO is Anirvan Ghosh. UNITY Biotechnology is focused on developing therapeutics aimed at alleviating age-related diseases by targeting cellular senescence. The company’s core product offerings include biologic treatments designed to eliminate senescent cells implicated in various degenerative conditions.

Their flagship products target significant health challenges such as osteoarthritis and retinal diseases leading to vision loss. These therapies aim to enhance the quality of life for aging individuals and are primarily marketed to aged populations with chronic health issues and healthcare providers in the United States and Europe. In 2022, UNITY Biotechnology generated revenue of USD 236,000 and reported an EBITDA of USD -30,304,000. Their revenue model is structured around partnerships with pharmaceutical companies and healthcare providers, facilitating the development and commercialization of their therapeutic products.

The company engages in B2B transactions, capitalizing on collaborations with major players in biotechnology, with revenue generation linked to milestone payments and royalties from licensing agreements. Following its IPO in May 2018, through which UNITY Biotechnology raised USD 85 mn, the company is strategically positioned to expand its product line and market reach. Plans include developing new therapeutics for additional age-related diseases and acquiring market shares in new geographic regions, specifically targeting European markets by 2025. The recent funding will support these initiatives, enabling further research and development efforts to enhance their therapeutic offerings and distribution capabilities.